When used for BRD treatment, DRAXXIN delivers better treatment success and outcomes than competitive products.
Other BRD treatments were 50% as effective as DRAXXIN®
In several large pen studies,5 DRAXXIN eclipsed competitive products with:
- 50% fewer re-treats6
- 50% fewer dead or chronic animals6
Three separate meta-analysis articles have demonstrated that DRAXXIN may reduce BRD mortality (control) or BRD case fatality rate (treatment) by 50% compared to competitive antimicrobials.8,9,10
In study after study, DRAXXIN® outperforms other antimicrobials, delivering better BRD control, superior cattle performance and more money in your pocket.
Greater first-time metaphylactic success
Cattle administered DRAXXIN on arrival were less likely to develop BRD than those given competitive antibiotics:
- 23% better success than Zuprevo® (tildipirosin)2
- 5.18% fewer BRD cases than Zactran® (gamithromycin)1
- Up to a 22.4% better than Micotil® (tilmicosin)3
- Up to a 21.8% better than Nuflor® (florfenicol)3
- 15.8% better than oxytetracycline4
Better BRD control than Zuprevo1
Compared with feedlot calves receiving Zuprevo on arrival, those administered DRAXXIN demonstrated:
- More than 76% reduction in deads and chronics1
- 18.5% better feed:gain1
- 30.9% increase in average daily gain1
Superior BRD control over Zactran2
Compared with feedlot calves receiving Zactran on arrival, those administered DRAXXIN demonstrated:
- 7.9% less BRD morbidity2
- 22.1% fewer BRD cases2
- 60.3% fewer BRD deads2
- 4.8% better daily gains and feed efficiency2
- A $38.96 per-head advantage2
IMPORTANT SAFETY INFORMATION: DRAXXIN has a pre-slaughter withdrawal time of 18 days in cattle. Do not use in female dairy cattle 20 months of age or older. Do not use in animals known to be hypersensitive to the product. See full Prescribing Information.
1 Data on file, Study Report No. A131R-US-12-028, Zoetis LLC.
2 Data on file, Study Report No. 11RGDRA01, Zoetis LLC.
3 Rooney KA, Nutsch RG, Skogerboe TL, et al. Efficacy of tulathromycin compared with tilmicosin and florfenicol for the control of respiratory disease in cattle at high risk of developing bovine respiratory disease. Vet Ther. 2005;6(2):154-66.
4 Booker CW, Abutarbush SM, Schunicht OC, et al. Evaluation of the efficacy of tulathromycin as a metaphylactic antimicrobial in feedlot calves. Vet Ther. 2007;8(3):183-200.
5 Data on file, Study Report Nos. 1133R-60-05-491, 1133R-60-05-492, 1133R-60-05-493, A131R-US-12-028, 2132T-60-01-050, 1133R-60-02-376, 2132T-60-01-063 and 1133R-60-03-388, Zoetis LLC.
6 Data on file, Study Report Nos. 1133R-60-05-491, A131R-US-12-028, 2132T-60-01-050, 1133R-60-02-376, 2132T-60-01-063, 1133R-60-03-388 and 11RGDRA01, Zoetis LLC.
7 Data on file, Study Report No. 15CARGOTH02, Zoetis LLC.
8 O’Connor AM, Coetzee JF, da Silva N and Wang C. A mixed treatment comparison meta-analysis of antibiotic treatments for bovine respiratory disease. Prev Vet Med. 2013; 110:77– 87.
9 Wellman NG, O’Connor AM. Meta-analysis of treatment of cattle with bovine respiratory disease with tulathromycin. J. Vet. Pharmacol Therap. 2007; 30:234–241.
10 Poulsen Nautrup B, Van Vlaenderen I, Gasper SM and Holland RE. Estimating the comparative clinical and economic consequences of tulathromycin for treatment of present or anticipated outbreaks of bovine respiratory disease in feedlot cattle in the United States. J Anim Sci. 2013; 91:5868-5877.
Baytril is a registered trademark of Bayer. Micotil is a registered trademark of Eli Lilly and Company. Nuflor and Zuprevo are trademarks of Merck Animal Health. Zactran is a registered trademark of Merial.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States